共 96 条
[1]
Chao EC(2010)SGLT2 inhibition-a novel strategy for diabetes treatment Nat. Rev. Drug Discov. 9 551-559
[2]
Henry RR(2011)Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans Diabetes 60 1561-1565
[3]
Nauck MA(2016)Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus Nat. Rev. Endocrinol. 12 566-592
[4]
Kemmeries G(2007)Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131-2157
[5]
Holst JJ(2016)Positioning SGLT2 inhibitors/ incretin-based therapies in the treatment algorithm Diabetes Care 39 S154-S164
[6]
Tahrani AA(2017)Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis BMJ 357 j2499-466
[7]
Barnett AH(2014)Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials Diabetes Obes. Metab. 16 457-697
[8]
Bailey CJ(2017)Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes Postgrad. Med. 129 686-784
[9]
Baggio LL(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann. Intern. Med. 162 777-1016
[10]
Drucker DJ(2016)Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial Lancet Diabetes Endocrinol. 4 1004-2146